Short Interest in Krystal Biotech, Inc. (NASDAQ:KRYS) Declines By 8.9%

Krystal Biotech, Inc. (NASDAQ:KRYS) was the target of a large decline in short interest during the month of January. As of January 15th, there was short interest totalling 3,370,000 shares, a decline of 8.9% from the December 31st total of 3,700,000 shares. Based on an average daily trading volume, of 247,300 shares, the short-interest ratio is presently 13.6 days.

Analyst Upgrades and Downgrades

Several research firms have recently commented on KRYS. HC Wainwright restated a “buy” rating and issued a $221.00 price objective on shares of Krystal Biotech in a research note on Wednesday, December 18th. Chardan Capital restated a “buy” rating and issued a $212.00 price objective on shares of Krystal Biotech in a research note on Wednesday, December 18th. Finally, Citigroup upped their price objective on Krystal Biotech from $204.00 to $206.00 and gave the stock a “neutral” rating in a research note on Tuesday, November 5th. One analyst has rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $206.67.

Insider Buying and Selling at Krystal Biotech

In other Krystal Biotech news, insider Suma Krishnan sold 25,000 shares of the business’s stock in a transaction on Friday, December 13th. The shares were sold at an average price of $164.78, for a total transaction of $4,119,500.00. Following the completion of the sale, the insider now directly owns 1,475,882 shares in the company, valued at approximately $243,195,835.96. The trade was a 1.67 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 14.10% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Wilmington Savings Fund Society FSB bought a new position in shares of Krystal Biotech during the 3rd quarter valued at about $40,000. Values First Advisors Inc. bought a new position in shares of Krystal Biotech during the 3rd quarter valued at about $53,000. GAMMA Investing LLC boosted its holdings in shares of Krystal Biotech by 184.8% during the 3rd quarter. GAMMA Investing LLC now owns 430 shares of the company’s stock valued at $78,000 after purchasing an additional 279 shares during the last quarter. Huntington National Bank boosted its holdings in shares of Krystal Biotech by 97.6% during the 3rd quarter. Huntington National Bank now owns 573 shares of the company’s stock valued at $104,000 after purchasing an additional 283 shares during the last quarter. Finally, Blue Trust Inc. boosted its holdings in shares of Krystal Biotech by 242.4% during the 3rd quarter. Blue Trust Inc. now owns 582 shares of the company’s stock valued at $107,000 after purchasing an additional 412 shares during the last quarter. Institutional investors own 86.29% of the company’s stock.

Krystal Biotech Stock Performance

Shares of Krystal Biotech stock opened at $159.74 on Monday. The company has a market capitalization of $4.59 billion, a P/E ratio of 90.25 and a beta of 0.84. The company has a fifty day moving average of $165.65 and a 200 day moving average of $179.28. Krystal Biotech has a fifty-two week low of $107.50 and a fifty-two week high of $219.34.

Krystal Biotech (NASDAQ:KRYS) last issued its earnings results on Monday, November 4th. The company reported $0.91 earnings per share for the quarter, topping the consensus estimate of $0.84 by $0.07. The company had revenue of $83.84 million during the quarter, compared to the consensus estimate of $82.94 million. Krystal Biotech had a net margin of 21.68% and a return on equity of 7.54%. Krystal Biotech’s quarterly revenue was up 879.9% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.67) EPS. Analysts forecast that Krystal Biotech will post 3.22 EPS for the current year.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).